AAVantgarde is a clinical stage, Italian-headquartered international biotechnology company with two proprietary AAV platforms for large-gene delivery
Mentions in press and media 3
| Date | Title | Description |
| 03.05.2024 | AAVantgarde presents the design of its innovative LUCE-1 trial for USH1B at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit | May 3, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of... |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting | MILAN, Italy, April 23, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, ... |
| 23.04.2024 | AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting | April 23, 2024 — AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication ... |